Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management

Lancet Infectious Diseases

Volumn 3, Issue 3, 2003, Pages 148-155

  Gardam, Michael A ^a,d   Keystone, Edward C ^b   Menzies, Richard ^c   Manners, Steven ^g   Skamene, Emil ^e   Long, Richard ^f   Vinh, Donald C ^e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d Division of Infectious Diseases   (Canada)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; METHOTREXATE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; GRANULOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SPONDYLOARTHROPATHY; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0037373957     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00545-0     Document Type: Review

References (75)

1. Dye C, Scheele S, Dolin P, et al. Consensus statement: WHO Global Surveillance and Monitoring Project. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999; 282: 677-86.
2. Long R, ed. Canadian Tuberculosis Standards, 5th edn. Canadian Lung Association, Health Canada, 2000.
3. Fenhalls G, Wong A, Bezuidenhout J, et al. In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas. Infect Immun 2000; 68: 2827-36.
4. Kaplan G, Freedman VH. The role of cytokines in the immune response to tuberculosis. Res Immunol 1996; 147: 565-72.
5. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
6. Manadan AM, Mohan AK, Cote TR, Siegel JN, Sequeira W, Block JA. Tuberculosis and etanercept. Proceedings of American College of Rheumatology Conference; October 2002; abstr 356.
7. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic implications. Gastroenterology 2000; 119: 1148-57.
8. Giacomini E, Iona E, Ferroni L, et al. Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response. J Immunol 2001; 166: 7033-41.
9. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
10. Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999; 162: 3504-11.
11. Pfeffer K, Matsuyama T, Kunding TM, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L monocytogenes infection. Cell 1993; 73: 457-67.
12. Jacobs M, Brown N, Allie N, et al. Tumor necrosis factor receptor 2 plays a minor role for mycobacterial immunity. Pathobiology 2000; 68: 68-75.
13. Havell EA. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 1989; 143: 2894-901.
14. Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukoc Biol 1991; 49: 380-87.
15. Kindler V, Sappino AP, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731-40.
16. Roach RR, Bean AGD, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 168: 4620-27.
17. Ehlers S, Benini J, Kutsch S, et al. Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium. Infect Immun 1999; 67: 3571-79.
18. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001; 69: 1847-55.
19. Turner J, Grank AA, Brooks JV, et al. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology. Immunology 2001; 102: 248-53.
20. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2: 561-72.
21. Keane J, Balcewicz-Sablinska MK, Remold HG, et al. Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect Immun 1997; 65: 298-304.
22. Balcewicz-Sablinska MK, Keane J, Kornfeld H, Remold HG. Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. J Immunol 1998; 161: 2636-41.
23. Saunders BM, Cooper AM. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol Cell Biol 2000; 78: 334-41.
24. Smith S, Liggitt D, Jeromsky E, et al. Local role for tumor necrosis factor alpha in the pulmonary inflammatory response to Mycobacterium tuberculosis infection. Infect Immun 2002; 70: 2082-89.
25. Kasahara K, Sato I, Ogura K, et al. Expression of chemokines and induction of rapid cell death in human blood neutrophils by Mycobacterium tuberculosis. J Infect Dis 1998; 178: 127-37.
26. Tsao TC, Hong J, Li LF, et al. Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-lbeta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis. Chest 2000; 117: 103-09.
27. Tracey KJ, Wei H, Manogue KR, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 1988; 167: 1211-27.
28. Tracey KJ, Cerami A. Tumor necrosis factor in the malnutrition (cachexia) of infection and cancer. Am J Trop Med Hyg 1992; 47: 2-7.
29. Cerami A, Ikeda Y, Le Trang N, et al. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett 1985; 11: 173-77.
30. Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor-α production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995; 1: 384-97.
31. Bekker L-G, Moreira AL, Bergtold A, et al. Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent. Infect Immun 2000; 68: 6954-61.
32. Rydberg J, Miorner H, Chandramuki A, Lantz M. Assessment of a possible imbalance between tumor necrosis factor (TNF) and soluble TNF receptor forms in tuberculous infection of the central nervous system. J Infect Dis 1995; 172: 301-04.
33. Falcone V, Bassey EB, Teniolo A, et al. Differential release of tumor necrosis factor alpha from murine peritoneal macrophages stimulated with virulent and avirulent species of mycobacteria. FEMS Immunol Med Microbiol 1994; 8: 225-32.
34. Knight DM, Trinh H, Le J,et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-53.
35. Scallon B, Cai A, Solowski N, et. al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-26.
36. Scallon BJ, Moore MA, Trinh H, et. al. Chimeric anti-TNF-alpha monoclonal antibody cA2binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251-59.
37. Lugering A, Schmidt M, Lugering N, et al. Infliximab induced apoptosis in monocytes from patients with chronic active Crohn's disease by using a Caspase-dependent pathway. Gastroenterology 2001; 121: 1145-57.
38. D'Auria F, Grazia Sabbadini M, Minutiello G, et al. Treatment with infliximab influences circulating nucleosomes in rheumatoid arthritis patients. Presented at 66th Annual Scientific Meeting of the American College of Rheumatology; October 2002; poster 262.
39. Lucas R, Tacchini-Cottier F, Guler R, et al. A role for lymphotoxin beta receptor in host defense against Mycobacterium bovis BCG infection. Eur J Immunol 1999; 29: 4002-10.
40. Remicade (infliximab) product monograph. Schering Canada. Compendium of pharmaceuticals and specialties. Toronto: Canadian Pharmacists Association: Webcom Ltd, 2002: 1443.
41. Enbrel (etanercept) product monograph. Wyeth Ayerst. Compendium of pharmaceuticals and specialties. Toronto: Canadian Pharmacists Association: Webcom Ltd, 2002: 569.
42. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932-39.
43. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
44. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
45. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-47.
46. Sweiss NJ, Ellman MH, Curran JJ, Park C. TNF-inhibition as novel treatment for refractory sarcoidoisis. Arthritis Rheum 2002; 46: s324.
47. Fahey SM, Bolster M, Silver RM, Judson M. Treatment of refractory sarcoidoisis with infliximab (Remicade). Arthritis Rheum 2002; 46: s323.
48. Brescia AC, McIlvain-Simpson G, Rose CD. Infliximab therapy for steroid-dependent early onset sarcoid arthritis and Blau syndrome. Arthritis Rheum 2002; 46: s313.
49. Misumi M, Hagiwara E, Nakamura S, et al. The alterations of cytokine production profile and interleukin-12 receptor expression before and after the treatment with infliximab in patients with Behcet's disease. Arthritis Rheum 2002; 46: s378.
50. Sfikakis PP, Kaklamanis P, Katsiari CG, Elezoglou A, Theodossiadis P, Markomichelakis N. Successful treatment of ocular relapse in patients with Behcet's disease with a single infusion of the anti-TNF agent infliximab. Arthritis Rheum 2002; 46: s181.
51. Munoz-Fernandez, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet 2001; 358: 295.
52. Kruithof E, Kestelyn P, Elewaut C, et al. Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Ann Rheum Dis 2002; 61: 470.
53. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
54. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-94.
55. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000; 356: 385-90.
56. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349-56.
57. Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001; 44: 1411-15.
58. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001; 45: 252-57.
59. Edwards CK. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-R1): novel high affinity TNF receptor designed for chronic inflammatory diseases. Ann Rheum Dis 1999; 58 (suppl 1): 173-81.
60. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis: the thalidomide experience. J Rheumatol 1989; 16: 158-63.
61. Keystone E, Weinblatt M, Furst D, et al. The ARMADA trial: a double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate (MTX) (abstract 965). Presented at the American College of Rheumatology 65th annual scientific meeting; San Francisco, CA, USA; Nov 11-15, 2001.
62. Keystone E, Choy E, Kalden J, et al. CDP870, a novel, pegylated, humanized TNF-A inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis (RA) (abstract LB-3). Presented at the American College of Rheumatology 65th annual scientific meeting; San Francisco, CA, USA; Nov 11-15, 2001.
63. Furst DE, Keystone E, Maini RN, Smolen JS. Recapitulation of the round-table discussion - assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 1999; 38 (suppl 2): 50-53.
64. Baker DG, Clark J, Keenan GF, Jones S. Tuberculosis occurring in patients receiving the anti-TNF agent infliximab (abstract 317). Presented at the American College of Rheumatology 65th annual scientific meeting; San Francisco, CA, USA; Nov 11-15, 2001.
65. Sabath DF, Wallis WJ, Burge DJ, Cook D, Viveash D. Lymphoma reports with etanercept therapy. Presented at the American College of Rheumatology Conference; October 2002; poster 1426.
66. American College of Rheumatology hotline. FDA advisory committee reviews safety of TNF inhibitors. http://www.rheumatology.org/research/hotline/0901tnf.html (accessed Dec 19, 2002).
67. Wallis WJ, Burge DJ, Sabath D, Gardiner M. Tuberculosis reports with etanercept (Enbrel) therapy. Presented at the American College of Rheumatology 65th annual scientific meeting; San Francisco, CA, USA; Nov 11-15, 2001 (abstr 153).
68. Wolfe F, Flowers N, Anderson J, Urbansky K. Tuberculosis rates are not increased in rheumatoid arthritis. Presented at the American College of Rheumatology 65th annual scientific meeting; San Francisco, CA, USA; Nov 11-15, 2001 (abstr 318).
69. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46: 2565-70.
70. Health Canada. Tuberculosis in Canada 1998. Publication H49-108/1998, ISBN 0-662-65491-9. Ottawa: Minister of Public Works and Government Services, 1998.
71. Cisneros JR, Murray KM. Corticosteroids in tuberculosis. Ann Pharmacother 1996; 50: 1298-303.
72. Kim HA, Yoo CD, Baek HJ, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998; 16: 9-13.
73. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161: 1376-95.
74. Anon. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States, 2001. MMWR Morb Mortal Wkly Rep 2001 2001; 50: 733-35.
75. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137: 640-47.